PerpEquities

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (A shares) (HENGRUI) cash flow statement

SHH · Healthcare · Drug Manufacturers - Specialty & Generic · 20,602 employees · CEO Sun Piaoyang

Price
CN¥48.97 +1.05%
Market cap
CN¥312B
Enterprise value
CN¥269B
Last report
Q3 '26 filed 2026-09-30
Next report
2027-04-19 EPS est. CN¥0.32

In Q3 '26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (A shares) (HENGRUI) generated CN¥5.88B of operating cash flow, invested CN¥1.09B in capital expenditure and kept CN¥4.78B of free cash flow. Over the last four quarters free cash flow was CN¥6.11B.

Cash flow

Cash flowTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating
Net incomeCN¥829MCN¥1.37BCN¥2.06BCN¥1.19BCN¥1.72BCN¥1.87BCN¥2.58BCN¥1.3BCN¥1.96BCN¥2.28BCN¥2.18BCN¥2.46B
Depreciation & amortizationCN¥222MCN¥212MCN¥212MCN¥223MCN¥223MCN¥231MCN¥231MCN¥240MCN¥240MCN¥0CN¥268MCN¥0
Stock-based compensationCN¥167MCN¥0CN¥110MCN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0
Deferred income tax-CN¥2.36BCN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0
Change in working capitalCN¥2.22BCN¥0-CN¥2.36BCN¥0CN¥0CN¥0-CN¥738MCN¥0CN¥0CN¥0-CN¥720MCN¥0
Other non-cash itemsCN¥2.26B-CN¥327MCN¥1.78BCN¥150MCN¥897M-CN¥1.53BCN¥1.69BCN¥3.51B-CN¥53.8M-CN¥1.5B-CN¥516MCN¥3.42B
Operating cash flowCN¥3.33BCN¥1.25BCN¥1.8BCN¥1.56BCN¥2.84BCN¥574MCN¥3.76BCN¥4.81BCN¥2.15BCN¥787MCN¥1.22BCN¥5.88B
Investing
Capital expenditure-CN¥113M-CN¥561M-CN¥404M-CN¥560M-CN¥445M-CN¥702M-CN¥566M-CN¥447M-CN¥1.25B-CN¥705M-CN¥873M-CN¥1.09B
AcquisitionsCN¥6.95MCN¥1.62MCN¥4.24MCN¥2.33MCN¥13.7MCN¥1.57M-CN¥579MCN¥584M-CN¥599MCN¥10.9MCN¥41.7MCN¥70.5M
Purchases of investments-CN¥14.9M-CN¥200M-CN¥400MCN¥0-CN¥22.7MCN¥0CN¥0CN¥0CN¥0-CN¥30.3M-CN¥285MCN¥0
Sales / maturities of investmentsCN¥106MCN¥9.01MCN¥26.2MCN¥208MCN¥415MCN¥169MCN¥10.3MCN¥1MCN¥21.4MCN¥519KCN¥0CN¥0
Other investingCN¥6.95MCN¥1.62M-CN¥370M-CN¥7.81MCN¥13.7M-CN¥17.2MCN¥2.15M-CN¥1CN¥11.8M-CN¥519KCN¥0CN¥0
Investing cash flow-CN¥15.3M-CN¥750M-CN¥799M-CN¥358M-CN¥38.5M-CN¥550M-CN¥1.14BCN¥139M-CN¥1.85B-CN¥724M-CN¥1.12B-CN¥1.02B
Financing
Net debt issued / repaidCN¥1.24BCN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥428M-CN¥433M-CN¥466K-CN¥1.61MCN¥354M
Share buybacks-CN¥827MCN¥0-CN¥110MCN¥110M-CN¥228MCN¥0-CN¥383MCN¥383M-CN¥978MCN¥0-CN¥243MCN¥243M
Dividends-CN¥165KCN¥0CN¥0-CN¥1.27BCN¥0CN¥0-CN¥1.27BCN¥0CN¥0CN¥0-CN¥1.33BCN¥0
Other financing (incl. tax on vested shares)-CN¥1.3B-CN¥18.1M-CN¥10.3M-CN¥94.2M-CN¥44.1M-CN¥661MCN¥10.9B-CN¥1.34BCN¥1.78B-CN¥185MCN¥166M-CN¥443M
Financing cash flow-CN¥54.5M-CN¥18.1M-CN¥120M-CN¥1.37B-CN¥44.1M-CN¥661MCN¥9.28B-CN¥529MCN¥302M-CN¥186M-CN¥1.4BCN¥153M
Summary
FX effect on cash-CN¥7.16M-CN¥18.2MCN¥12.4M-CN¥15.4MCN¥28.6MCN¥29.6MCN¥143M-CN¥178M-CN¥9.99M-CN¥306M-CN¥488M-CN¥294M
Net change in cashCN¥3.26BCN¥468MCN¥1.01B-CN¥181MCN¥2.78B-CN¥608MCN¥12BCN¥4.24BCN¥591M-CN¥429M-CN¥1.79BCN¥4.71B
Free cash flow (OCF - capex)CN¥3.22BCN¥694MCN¥1.4BCN¥1BCN¥2.39B-CN¥147MCN¥3.19BCN¥4.36BCN¥899MCN¥82.1MCN¥343MCN¥4.78B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates: Financial Modeling Prep.

Data as of 2026-11-02